Medifast (MED) 10-K 16 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Mar. 02, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	MEDIFAST INC
Entity Central Index Key	910,329
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Public Float			$ 349
Entity Common Stock, Shares Outstanding		11,906,286

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 52,436	$ 42,037
Accounts receivable-net of allowance for sales returns and doubtful accounts of $449 and $417	1,387	1,633
Inventory	18,311	13,335
Investment securities	24,412	25,072
Income taxes, prepaid	1,249	1,549
Prepaid expenses and other current assets	3,502	2,886
Current assets of discontinued operations		353
Total current assets	101,297	86,865
Property, plant and equipment - net	19,753	29,029
Other assets	162	205
Long-term assets of discontinued operations	4	19
TOTAL ASSETS	121,216	116,118
Current liabilities:
Accounts payable and accrued expenses	24,300	22,504
Current maturities of capital leases		219
Current liabilities of discontinued operations	121	841
Total current liabilities	24,421	23,564
Other liabilities:
Deferred tax liabilities	779	3,682
Long-term liabilities of discontinued operations		288
Total liabilities	25,200	27,534
Stockholders' Equity:
Common stock; par value $.001 per share; 20,000 shares authorized; 12,027 and 12,014 issued at December 31, 2016 and 2015, respectively 11,871 and 11,797 outstanding December 31, 2016 and 2015, respectively	12	12
Additional paid-in capital	2,672
Accumulated other comprehensive income/(loss)	(165)	(62)
Retained earnings	93,497	88,634
Total stockholders' equity	96,016	88,584
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 121,216	$ 116,118

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for sales returns and doubtful accounts	$ 449	$ 417
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	20,000,000	20,000,000
Common stock, issued	12,027,000	12,014,000
Common stock, outstanding	11,871,000	11,797,000

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenue	$ 274,534	$ 272,773	$ 285,285
Cost of sales	68,870	71,458	76,078
Gross Profit	205,664	201,315	209,207
Selling, general, and administrative	178,805	172,631	178,961
Income from operations	26,859	28,684	30,246
Other income (expense)
Interest and dividend income, net	283	661	716
Other income (expense)	(20)	326	731
Nonoperating Income (Expense)	263	987	1,447
Income from continuing operations before income taxes	27,122	29,671	31,693
Provision for income taxes	9,287	10,104	10,664
Income from continuing operations	17,835	19,567	21,029
Income (loss) from discontinued operations, net of tax		491	(7,848)
Net income	$ 17,835	$ 20,058	$ 13,181
Basic earnings (loss) per share
Earnings per share from continuing operations	$ 1.51	$ 1.64	$ 1.66
Earnings (loss) per share from discontinued operations		0.04	(0.62)
Earnings per share	1.51	1.68	1.04
Diluted earnings (loss) per share
Earnings per share from continuing operations	1.49	1.62	1.65
Earnings (loss) per share from discontinued operations		0.04	(0.62)
Earnings per share	$ 1.49	$ 1.66	$ 1.03
Weighted average shares outstanding -
Basic	11,842	11,959	12,670
Diluted	11,947	12,071	12,778
Cash dividends declared per share	$ 1.07	$ 0.25

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement Of Other Comprehensive Income [Abstract]
Net income	$ 17,835	$ 20,058	$ 13,181
Other comprehensive income, net of tax
Change in foreign currency translation, net of tax	7	64
Change in fair value of marketable securities, net of tax	(175)	(245)	207
Adjustment for net (gains)/losses realized and included in net income, net of tax	65	(316)	(475)
Total change in unrealized losses on marketable securities, net of tax	(110)	(561)	(268)
Other comprehensive loss	(103)	(497)	(268)
Comprehensive income	$ 17,732	$ 19,561	$ 12,913

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid- In Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]	Treasury Stock [Member]	Total
Balance at Dec. 31, 2013	$ 13		$ 97,700	$ 703		$ 98,416
Balance (in shares) at Dec. 31, 2013	13,143
Share-based compensation		$ 3,918				3,918
Share-based compensation (in shares)	387
Net shares repurchased for employee taxes		(1,152)				(1,152)
Net shares repurchased for employee taxes (in shares)	(38)
Share-based compensation tax benefit		275				275
Treasury stock purchases					$ (33,894)	(33,894)
Treasury stock retirement	$ (1)	(1,909)	(31,984)		33,894
Treasury stock retirement (in shares)	(1,127)
Net income			13,181			13,181
Other comprehensive loss				(268)		(268)
Balance at Dec. 31, 2014	$ 12	1,132	78,897	435		80,476
Balance (in shares) at Dec. 31, 2014	12,365
Options exercised by executives and directors		44				44
Options exercised by executives and directors (in shares)	2
Share-based compensation		3,081				3,081
Share-based compensation (in shares)	51
Net shares repurchased for employee taxes		(1,296)				(1,296)
Net shares repurchased for employee taxes (in shares)	(40)
Share-based compensation tax benefit		247				247
Cash dividends declared to stockholders			(3,013)			(3,013)
Treasury stock purchases					(10,516)	(10,516)
Treasury stock retirement		(3,208)	(7,308)		$ 10,516
Treasury stock retirement (in shares)	(364)
Net income			20,058			20,058
Other comprehensive loss				(497)		(497)
Balance at Dec. 31, 2015	$ 12		88,634	(62)		88,584
Balance (in shares) at Dec. 31, 2015	12,014
Options exercised by executives and directors		299				299
Options exercised by executives and directors (in shares)	12
Share-based compensation		3,428				3,428
Share-based compensation (in shares)	41
Net shares repurchased for employee taxes		(1,285)	(57)			(1,342)
Net shares repurchased for employee taxes (in shares)	(40)
Share-based compensation tax benefit		230				230
Cash dividends declared to stockholders			(12,915)			(12,915)
Net income			17,835			17,835
Other comprehensive loss				(103)		(103)
Balance at Dec. 31, 2016	$ 12	$ 2,672	$ 93,497	$ (165)		$ 96,016
Balance (in shares) at Dec. 31, 2016	12,027

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income	$ 17,835	$ 20,058	$ 13,181
Income from discontinued operations, net of tax		491	(7,848)
Income from continuing operations	17,835	19,567	21,029
Adjustments to reconcile net income to net cash provided by operating activities from continuing operations:
Depreciation and amortization	5,405	7,115	8,052
Realized (gain)/loss on investment securities, net	313	(458)	(771)
Share-based compensation	3,428	3,081	3,918
Deferred income taxes	(2,829)	(106)	286
Impairment of fixed assets	6,083
(Gain)/loss on disposal of fixed assets	(12)	81	(29)
Changes in assets and liabilities which provided (used) cash:
Accounts receivable	246	17	(708)
Inventory	(4,976)	2,400	1,802
Prepaid expenses and other current assets	(616)	(56)	(349)
Other assets	43	292	(318)
Accounts payable and accrued expenses	770	(2,363)	(376)
Income taxes, prepaid	300	3,550	(5,198)
Net cash provided by operating activities- continuing operations	25,990	33,120	27,338
Net cash used in operating activities- discontinued operations	(640)	(3,709)	(1,802)
Net cash provided by operating activities	25,350	29,411	25,536
Cash Flow from Investing Activities:
Sale of investment securities	26,741	11,880	29,636
Purchase of investment securities	(26,578)	(9,250)	(26,080)
Sale of property and equipment	676
Purchase of property and equipment	(2,876)	(2,819)	(7,024)
Net cash used in investing activities- continuing operations	(2,037)	(189)	(3,468)
Net cash provided by investing activities- discontinued operations			950
Net cash used in investing activities	(2,037)	(189)	(2,518)
Cash Flow from Financing Activities:
Repayment of capital leases	(219)	(255)	(222)
Decrease in note receivable		45	52
Net shares repurchased for employee taxes	(1,342)	(1,296)	(1,152)
Options exercised by executives and directors	299	44	0
Excess tax benefits from share-based compensation	230	247	275
Purchase of treasury stock		(10,516)	(33,894)
Cash dividends paid to stockholders	(11,889)
Net cash used in financing activities	(12,921)	(11,731)	(34,941)
Foreign currency impact	7	87
NET CHANGE IN CASH AND CASH EQUIVALENTS	10,399	17,578	(11,923)
Cash and cash equivalents - beginning of the period	42,037	24,459	36,382
Cash and cash equivalents - end of period	52,436	42,037	24,459
Supplemental disclosure of cash flow information:
Interest paid	24	22	131
Income taxes paid	11,615	4,182	$ 12,721
Dividends declared included in accounts payable	$ 4,039	$ 3,013

Nature of the Business

Nature of the Business	12 Months Ended
	Dec. 31, 2016
Nature of the Business [Abstract]
Nature of the Business	1. NATURE OF THE BUSINESS Medifast, Inc. (the “Company” or “Medifast”) is a Delaware corporation, incorporated in 1989. The Company’s operations are primarily conducted through eight of its wholly owned subsidiaries, Jason Pharmaceuticals, Inc., Optavia LLC, Take Shape For Life, LLC, Jason Enterprises, Inc., Jason Properties, LLC, Medifast Franchise Systems, Medifast Nutrition, Inc. and Seven Crondall, LLC. The Company is engaged in the production, distribution, and sale of weight loss, weight management, and healthy living products and other consumable health and nutritional products. Medifast product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products and vitamins. The Company has one modern, Food and Drug Administration (“FDA”)-approved manufacturing facility located in Owings Mills, Maryland. These products are sold through various means, including the internet, call center, independent health advisors, medical professionals, franchise weight loss clinics, and direct consumer marketing supported via the phone and internet. The processing, formulation, packaging, labeling and advertising of the Company’s products are subject to regulation by one or more federal agencies, including the FDA, the Federal Trade Commission (“FTC”), the Consumer Product Safety Commission, the United States Department of Agriculture, and the United States Environmental Protection Agency.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant accounting policies followed in the preparation of the consolidated financial statements are as follows: Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Jason Pharmaceuticals, Inc., Take Shape For Life, LLC, Seven Crondall Associates, LLC, Jason Properties, LLC, Medifast Franchise Systems, Inc., Medifast Nutrition, Inc., Optavia LLC, Performance Products LLC, and Jason Enterprises, Inc. All inter-Company transactions and balances have been eliminated in consolidation. Reclassification – Certain amounts reported for prior periods have been reclassified to be consistent with the current period presentation. No reclassification in the consolidated financial statements had a material impact on the presentation except the reclassification of all deferred tax assets and deferred tax liabilities as noncurrent in accordance with the Company’s early adoption of ASU 2015-17 during the fourth quarter of 2016. Use of Estimates – The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates. Cash and Cash Equivalents - Cash and cash equivalents consist of cash on deposit in financial institutions, institutional money funds and other short-term investments with a maturity of 90 days or less at the time of purchase. Concentration of Credit Risk – Our cash and cash equivalents and available-for-sale securities are maintained at several financial institutions, and the balances with these financial institutions often exceed the amount of insurance provided on such accounts by the Federal Deposit Insurance Corporation. The cash and cash equivalents generally are maintained with financial institutions with reputable credit, and therefore bear minimal credit risk. Historically, we have not experienced any losses due to such concentration of credit risk. Fair Value of Financial Instruments - Our financial instruments include cash and cash equivalents, investment in available-for-sale securities, and trade receivables. The carrying amounts of cash and cash equivalents, and trade receivables approximate fair value due to their short maturities. The fair values of investment in available-for-sale securities are based on dealer quotes. Accounts Receivable and Allowance for Sales Returns and Doubtful Accounts - Accounts receivable are recorded net of reserves for sales returns and allowances, and net of provisions for doubtful accounts. We review the reserves for customer returns at each reporting period and adjust them to reflect data available at that time. To estimate reserves for returns, we consider actual return rates in preceding periods. To the extent the estimate of returns changes, we will adjust the reserve, which will impact the amount of product sales revenue recognized in the period of the adjustment. Our estimates for returns have not differed materially from our actual returns. The provision for estimated returns as of December 31, 2016 and 2015 was $394,000 and $323,000 , respectively. Allowances for doubtful accounts are based primarily on an analysis of aged accounts receivable balances and the credit worthiness of our customers as determined by credit checks and analysis, as well as customer payment history. The allowance for doubtful accounts as of December 31, 2016 and 2015 was $55,000 and $94,000 , respectively. Inventory - Inventories consist principally of packaged meal replacements held in the Company’s warehouses. Inventory is stated at the lower of cost or market, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventory for unsalable or obsolete inventory. Investment Securities – The Company’s investments consist of debt and equity securities classified as available-for-sale securities. Available-for-sale securities are stated at fair value, and unrealized holding gains and losses, net of the related deferred tax effect, are reported as a separate component of accumulated other comprehensive income in stockholders' equity. Interest and dividends on marketable debt and equity securities are recognized in income when declared. Realized gains and losses, including losses from declines in value of specific securities determined by management to be other-than-temporary, if any, are included in income. Income Taxes – The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. We evaluated our tax positions and determined that we did not have any material uncertain tax positions. Our policy is to recognize interest and penalties accrued on uncertain tax positions as part of income tax expense. For the years ending December 31, 2016 and 2015, no material estimated interest or penalties were recognized for the uncertainty of certain tax positions. We file income tax returns in the United States, Canada and various states jurisdictions. We are no longer subject to U.S. federal, state, and local income tax examinations by tax authorities for the years before 2013. Deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Advertising Costs - Advertising costs are expensed as incurred, except for the preparation, layout, design and production of advertising costs which are expensed when the advertisement is first used. Advertising expense for continuing operations, excluding broker fees, for the years ended December 31, 2016, 2015, and 2014, amounted to $ 9.4 million, $15.3 million, and $ 17.0 million, respectively. Operating Leases - Medifast leases retail stores, distribution facilities, and office space under operating leases. Many of our lease agreements contain tenant improvement allowances, rent holidays, rent escalation clauses, and contingent rent provisions. The Company recognizes incentives and minimum rental expenses on a straight-line basis over the terms of the leases. We commence recording rent expense on the date of initial possession, which is generally when we enter the space and begin to make improvements to properties for our intended use. For tenant improvement allowances and rent holidays, we record a deferred rent liability on the consolidated balance sheets and amortize the deferred rent over the terms of the leases as reductions to rent expense on the consolidated statements of income. For scheduled rent escalation clauses during the lease terms or for rental payments commencing at a date other than the date of initial occupancy, we record minimum rental expenses on a straight-line basis over the terms of the leases on the consolidated statements of income. Several leases provide for contingent rents, which are determined as a percentage of gross sales in excess of specified levels. We record a contingent rent liability on the consolidated balance sheets and the corresponding rent expense when we determine achieving the specified levels is probable. Clinic Closure Costs - Clinic closure costs are expensed and recognized as a liability at their fair value when incurred. One-time employee severance costs are expensed and recognized as a liability when the plan is finalized by management, approved and committed to by management, and communicated to the employee. Contractual costs that will continue to be incurred (operating leases) are recognized at the cease use date. The fair value of operating lease contracts is determined based on the present value of the remaining lease payments. Other costs associated with closing the clinic or relocating employees are expensed as incurred. Property, Plant, and Equipment - Property, plant and equipment are stated at cost less accumulated depreciation and amortization. The Company computes depreciation and amortization using the straight-line method over the estimated useful lives of the assets acquired as follows:    Building and building improvements 10 - 35 years  Equipment and fixtures 3 - 15 years  Leasehold Improvements Lease term  Vehicles 5 years  The depreciation life for leasehold improvements is the lesser of the estimated useful life of the addition or the term of the related lease. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Research and Development- The Company incurs research and development costs in connection with the development of new products and programs, which are expensed as incurred. The Company also invests in studies to evaluate the effectiveness of our products and programs, the costs of which are recognized evenly over the duration of the study. The Company incurred $2.0 million, $1.8 million, and $1.3 million in research and development expense for the years ended December 31, 2016, 2015, and 2014, respectively. Revenue Recognition - Revenue is recognized net of discounts, rebates, promotional adjustments, price adjustments, and estimated returns and upon transfer of title and risk to the customer which occurs at shipping (F.O.B. terms). Upon shipment, the Company has no further performance obligations and collection is reasonably assured as the majority of sales are paid prior to shipping. Medifast Weight Control Centers program fees were recognized over the estimated service period. Shipping and Handling Costs - Our shipping and handling costs for shipments of our product to our customers are included in cost of sales. All shipping and handling charges that are billed to customers are included in net revenue. All other shipping and handling costs are included in selling, general and administration expenses. Earnings per Share - Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of shares of common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of common stock outstanding adjusted for the effect of dilutive common stock equivalents. The following table sets forth the computation of basic and diluted EPS:    Years Ended December 31,  2016 2015 2014  Numerator:  Income from continuing operations $ 17,835 $ 19,567 $ 21,029  Income/(loss) from discontinued operations - 491 (7,848)  Net income $ 17,835 $ 20,058 $ 13,181   Denominator:  Weighted average shares of common stock outstanding 11,842 11,959 12,670  Effect of dilutive common stock equivalents 105 112 108   Weighted average shares of common stock outstanding 11,947 12,071 12,778   EPS:  Basic earnings (loss) per share  Earnings per share from continuing operations $ 1.51 $ 1.64 $ 1.66  Earnings (loss) per share from discontinued operations $ - $ 0.04 $ (0.62)  Earnings per share $ 1.51 $ 1.68 $ 1.04   Diluted earnings per share  Earnings per share from continuing operations $ 1.49 $ 1.62 $ 1.65  Earnings (loss) per share from discontinued operations $ - $ 0.04 $ (0.62)  Earnings per share $ 1.49 $ 1.66 $ 1.03  The calculation of diluted earnings per share excluded 35,000 , 69,375 and 67,375 antidilutive options outstanding for the years ended December 31, 2016, 2015, and 2014 respectively. The calculation of diluted earnings per share for the year ended December 31, 2016 also excluded 93 antidilutive restricted stock awards. Share-Based Compensation - Share-based compensation consists primarily of restricted stock awards, market- and performance-based share awards, and stock options granted to employees and directors. Restricted stock awards are measured at the grant date, based on the calculated fair value of the award, and are recognized as an expense over the requisite service period. The fair value of the incentive stock options and non-qualified stock options is calculated using the Black-Scholes option pricing model as of the grant date and recognized over the service period. Market and performance-based share awards that are tied to the Company’s total shareholder return and stock price are valued using the Monte Carlo method and are recognized as expense over the award’s achievement period. The Company issues new shares upon the exercise of stock options and the granting of restricted stock awards. Comprehensive Income - Other comprehensive income refers to revenues, expenses, gains and losses that are not included in net income but rather are recorded directly in stockholders’ equity. Comprehensive income consists of net income, unrealized gains and losses on available-for-sale securities, and foreign currency translation adjustments. Recent Accounting Pronouncements We have considered all new accounting pronouncements and have concluded that there are no new pronouncements that may have a material impact on our results of operations, financial condition, or cash flows, based on current information, except for: ASU 2016-09, Compensation- Stock Compensation (Topic 718): Improvements to Employee Share-Based Payable Accounting allows for the simplification of accounting for stock compensation in relation to income taxes, classification of awards as equity or liabilities and classification on the statement of cash flows. The pronouncement is effective for fiscal years beginning after December 15, 2016. Management has evaluated the pronouncement and determined that it will not have a material impact on the Company’s financial statements. ASU 2016-02, Leases (Topic 842) requires the rights and obligations of all leased assets with a term greater than 12 months to be presented on the balance sheet. The pronouncement is effective for fiscal years beginning after December 15, 2018. Management is currently evaluating the effect that the provisions of ASU 2016-02 will have on the Company’s financial statements. ASU 2016-01, Financial Instruments- Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities , most notably requires the changes in fair value of equity investments to be recognized in net income. The pronouncement also requires the use of the exit price notion, the separate presentation of financial assets and liabilities by measurement category and form of asset, and the separate presentation in other comprehensive income of changes in fair value resulting from a change in the instrument-specific credit risk. The pronouncement is effective for fiscal years beginning after December 15, 2017. Based on the risk level of the Company’s investment portfolio, Management does not expect the pronouncement to have a material impact on the Company’s financial statements. ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory , requires the Company to recognize inventory at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling price in the ordinary course of business less costs of completion, disposal, and transportation. The pronouncement is effective for fiscal years beginning after December 31, 2016. Management has evaluated the pronouncement and determined that it will not have a material impact on the Company’s financial statements. ASU 2015-09, Revenue from Contracts with Customers (Topic 606) , requires the Company to recognize revenue for the transfer of goods or services to customers for the amount the Company expects to be entitled to in exchange for those goods or services. The Company will be required to identify the contract, identify the relevant performance obligations, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when the entity satisfies a performance obligation. The provisions of this ASU are effective for interim and annual periods beginning after December 15, 2017. Management is evaluating the effect that the provisions of ASU 2015-09 will have on the Company’s financial statements .

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2016
Financial Instruments [Abstract]
Financial Instruments	3. FINANCIAL INSTRUMENTS  Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:  Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.  Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.  Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value from the perspective of a market participant.  The following table represents cash and the available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or investment securities as of:      December 31, 2016  Cost Unrealized Gains Unrealized Losses Accrued Interest Estimated Fair Value Cash & Cash Equivalents Investment Securities   Cash $ 52,005 $ - $ - $ - $ 52,005 $ 52,005 $ -   Level 1:  Money market accounts 431 - - - 431 431 -  Government & agency securities 2,655 - (48) 9 2,616 - 2,616  3,086 - (48) 9 3,047 431 2,616   Level 2:  Municipal bonds 21,836 - (348) 308 21,796 - 21,796  21,836 - (348) 308 21,796 - 21,796   Total $ 76,927 $ - $ (396) $ 317 $ 76,848 $ 52,436 $ 24,412       December 31, 2015  Cost Unrealized Gains Unrealized Losses Accrued Interest Estimated Fair Value Cash & Cash Equivalents Investment Securities   Cash $ 38,276 $ - $ - $ - $ 38,276 $ 38,276 $ -   Level 1:  Money market accounts 3,761 - - - 3,761 3,761 -  Mutual funds 9,654 37 (444) - 9,247 - 9,247  Corporate equity securities 1,332 246 (76) - 1,502 - 1,502  Government & agency securities 5,425 25 (19) 17 5,448 - 5,448  20,172 308 (539) 17 19,958 3,761 16,197   Level 2:  Municipal bonds 2,735 42 (3) 20 2,794 - 2,794  Corporate bonds 6,054 22 (41) 46 6,081 - 6,081  8,789 64 (44) 66 8,875 - 8,875   Total $ 67,237 $ 372 $ (583) $ 83 $ 67,109 $ 42,037 $ 25,072  The Company had a realized loss of $313 thousand for the year ended December 31, 2016, and realized gains of $458 thousand and $771 thousand for the years ended December 31, 2015 and 2014, respectively. As of December 31, 2016, 2015, and 2014, gross unrealized losses related to individual securities that had been in a continuous loss position for 12 months or longer were not significant. The maturities of the Company’s investment securities generally range up to 5 years for municipal bonds and for government and agency securities.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2016
Inventories [Abstract]
Inventories	  4. INVENTORIES Inventories consist principally of packaged meal replacements held in the Company’s warehouses. Inventory is stated at the lower of cost or market, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventory for unsalable or obsolete inventory. Inventories consisted of the following as of:    December 31, 2016 December 31, 2015  Raw materials $ 6,015 $ 3,666  Packaging 1,202 788  Non-food finished goods 701 635  Finished goods 11,219 8,545  Reserve for obsolete inventory (826) (299)  $ 18,311 $ 13,335 

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	5. PROPERTY, PLANT AND EQUIPMENT Property, plant, and equipment consisted of the following as of:    December 31, 2016 December 31, 2015  Land $ 565 $ 650  Building and leasehold improvements 12,698 13,122  Equipment and fixtures 42,342 61,573  Vehicles 149 149  $ 55,754 $ 75,494  Less accumulated depreciation and amortization 36,001 46,465  Property, plant and equipment- net $ 19,753 $ 29,029  Depreciation and amortization expense for continuing operations for the years ended December 31, 2016, 2015 and 2014 was $5.4 million , $7.1 million , and $8.1 million , respectively. The Company did not incur any depreciation and amortization expense for discontinued operations related to the Medifast Corporate Weight Control Centers for the years ended December 31, 2016 and 2015, and incurred $1.7 million for the year ended December 31, 2014. As a result of the sale and closure of the Medifast Weight Control Centers, the Company incurred an asset impairment loss of $3.3 million in 2014 that is included in discontinued operations.

Accounts Payable And Accrued Ex

Accounts Payable And Accrued Expenses	12 Months Ended
	Dec. 31, 2016
Accounts Payable and Accrued Expenses [Abstract]
Accounts Payable and Accrued Expenses	6. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consisted of the following as of:    December 31, 2016 December 31, 2015  Trade payables $ 9,580 $ 11,264  Sales commissions payable 4,757 4,245  Accrued payroll and related taxes 5,402 3,440  Dividends payable 4,039 3,013  Sales tax payable 522 542  $ 24,300 $ 22,504 

Leases

Leases	12 Months Ended
	Dec. 31, 2016
Leases [Abstract]
Leases	  7. LEASES Operating Leases: As of December 31, 2016, the Company leases office space for corporate offices, a distribution facility in Texas, a raw materials warehouse in Maryland, as well as 20 previously corporate-operated Medifast Weight Control Centers under lease terms ranging from five to ten years. The 20 leases include 3 closed Centers and 17 leases for Centers that were sold to franchise partners during 2014 and entered into sublease agreements with the franchisees. The Company accrued for the remaining lease obligations net of any sublease income in 2014, see Note 11 for exit activity and clinic obligations. Monthly payments under the Medifast Weight Control Centers leases range in price from $1,800 to $4,200 . The Company is additionally required to pay property taxes, utilities, insurance and other costs relating to the leased facilities. The following table summarizes our future minimum rental and lease payments required under non-cancelable original lease terms in excess of one year as of December 31, 2016:    Operating Leases  2017 $ 1,773  2018 296  2019 21  Total minimum lease payments $ 2,090  Total minimum lease payments have not been reduced by minimum sublease rent income of approximately $0.8 million due under future non-cancelable subleases. The following is a summary of the Company’s rent expense for the years ended December 31, 2016, 2015 and 2014:    2016 2015 2014   Continuing operations $ 1,276 $ 1,506 $ 1,460  Discontinued operations - (1,002) 7,189  $ 1,276 $ 504 $ 8,649  For the year ended December 31, 2015, the positive impact to rent expense was due to lease termination agreements that resulted in the reversal of rent obligations estimates that were expensed in 2014. For the year ended December 31, 2014 the discontinued operations rent expense includes an accrual of $4.4 million for continuing obligations for operating leases related to centers closed during the periods. Equipment lease expense for continuing operations for the years ended December 31, 2016, 2015, and 2014 was $0.7 million, $1.0 million, and $1.2 million, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Income Taxes	  8. INCOME TAXES The components of the income tax expense from continuing operations for the years ended December 31, 2016, 2015, and 2014 are as follows:    2016 2015 2014  Current  Federal $ 11,605 $ 9,814 $ 10,282  State 511 396 96  Total current 12,116 10,210 10,378   Deferred  Federal (3,078) (125) 176  State 253 39 206  Foreign (4) (20) (96)  Total deferred (2,829) (106) 286   Total income tax expense from continuing operations $ 9,287 $ 10,104 $ 10,664  The total tax provision for the years ended December 31, 2016, 2015, and 2014 was $ 9.0 million, $9.9 million, $4.9 million, respectively. Those amounts have been allocated to the following financial statement items:    2016 2015 2014   Income from continuing operations $ 9,287 $ 10,104 $ 10,664  Income/(loss) from discontinued operations - 387 (5,302)  Stockholders' equity, unrealized gain loss on investment securities & foreign currency (74) (357) (182)  Additional paid in capital, share-based compensation tax benefit (230) (247) (275)   Total income tax expense $ 8,983 $ 9,887 $ 4,905  The Company elected to early adopt pronouncement ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes , as of December 31, 2016 and applied its provisions retrospectively to each prior period presented for comparative purposes. The provision requires the Company to classify all deferred tax assets and liabilities as noncurrent, For the year s ended December 31, 2016 , 2015, and 2014 , the Company reclassified $1.7 million , $1.2 million, and $3.7 million, respectively, in current net deferred tax assets against the Company’s non-current deferred tax liability. Deferred tax assets (liabilities) consisted of the following at December 31,    2016 2015 2014   Reserves on inventory and sales $ 446 $ 199 $ 291  Credit and loss carryforwards 527 735 699  Stock compensation 1,333 1,149 1,283  Accrued expenses and deferred costs 638 1,068 3,170  Inventory capitalization 252 49 142  Sales tax accrual - - 8  Unrealized gain on investments 160 85 -  Total deferred tax assets 3,356 3,285 5,593   Unrealized loss on investments - - (294)  Prepaid expenses (659) (755) (779)  Depreciation (3,453) (6,189) (6,285)  Foreign currency (23) (23) -  Total deferred tax liabilities (4,135) (6,967) (7,358)   Net deferred tax liabilities $ (779) $ (3,682) $ (1,765)  The differences between the United States federal statutory tax rate and the Company's effective tax rate for the years ended December 31, 2016, 2015, and 2014 are as follows:    2016 2015 2014  Statutory federal tax $ 9,493 35.0% $ 10,381 35.0% $ 11,093 35.0%  State income taxes, net of federal benefit 797 2.9% 414 1.4% 314 1.0%  Foreign Taxes 3 0.0% 15 0.1% 73 0.2%  Domestic manufacturer deduction (920) -3.4% (824) -2.8% (811) -2.6%  Other permanent differences 41 0.2% 4 0.0% 200 0.6%  Research and development and jobs credits (163) -0.6% (247) -0.8% (203) -0.6%  Other state income tax benefits - 0.0% 114 0.4% (113) -0.4%  Other 36 0.1% 247 0.8% 111 0.4%  $ 9,287 34.2% $ 10,104 34.1% $ 10,664 33.6%  The 2016 , 2 015 and 2014 effective tax rates were impacted by the Company’s extensive state income tax planning. This planning includes taking advantage of Maryland’s apportionment methodology. As a manufacturing entity based in Maryland, the Company utilizes the single sales factor apportionment method in addition to claiming new state jobs credits and research & development credits. In 2014 the Company benefited from research and development credits effective January 1, 2014 in addition to filing an amended federal return to claim 2010 research and development credits due to changes in Federal regulations. The Company has separate company state net operating loss carry forwards totaling $ 8.0 million that start expiring in 2031 and a capital loss carryforward totaling $110 thousand that expires in 2022 . Maryland state credits carry forwards totaling $116 thousand w ill begin to expire in 201 7 .

Shared-based Compensation

Shared-based Compensation	12 Months Ended
	Dec. 31, 2016
Share-based Compensation [Abstract]
Shared-based Compensation	9. SHARED-BASED COMPENSATION Stock Options: The Company has issued non-qualified and incentive stock options to employees and nonemployee directors. The fair value of these options are estimated on the date of grant using the Black-Scholes option pricing model, which requires estimates of the expected term of the option, the expected volatility of the price of the Company’s common stock, dividend yield and the risk-free interest rate. Options outstanding as of December 31, 2016 generally vest over a period of three years with an expiration term of ten years. The exercise price of these options ranges from $24.26 to $31.55 . The expected volatility is based on the historical volatility of the Company’s common stock over the period of time equivalent to the expected term for each award. Due to the Company’s lack of option exercise history, the expected term is calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each award. The risk free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant which most closely corresponds to the expected term of the option. The Company declared its first dividend in December 2015; and therefore, a dividend yield was not utilized in the Black-Scholes calculation for options granted prior to December 2015. The weighted average input assumptions used and resulting fair values were as follows:    2016 2015 2014  Expected term (in years) 6 6 6  Risk-free interest rate 1.11% 1.71% 1.61%  Expected volatility 42.22% 50.91% 63.15%  Dividend yield 3.56% - -     The following table summarizes the stock option activity:    Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (Yrs) Aggregate Intrinsic Value  Outstanding at December 31, 2015 98 $ 28.17  Granted 50 27.99  Exercised (12) 25.64  Forfeited (6) 29.87  Expired (1) 31.55  Outstanding at December 31, 2016 129 $ 28.22 8.20 $ 1,736  Exercisable at December 31, 2016 49 $ 27.45 7.31 $ 689     The weighted-average grant date fair value of op tions granted during 2016 was $7.91 . The unrecognized compensation expense calculated under the fair value method for shares expected to vest as of December 31, 2016 was approximately $0.5 million and is expected to be recognized over a weighted average period of 1.7 years. The Company received $0.3 million and $44 thousand in cash proceeds from the exercise of stock options during the years ended December 31, 2016 and 2015, respectively. The total intrinsic value of options exercised during the years ended December 31, 2016 and 2015 was $69 thousand and $10 thousand, respectively. No options were exercised in 2014.  Restricted Stock: The Company has issued restricted stock to employees and nonemployee directors generally with vesting terms up to five years after the date of grant. The fair value is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period. The following table summarizes the restricted stock activity:    Shares Weighted-Average Grant Date Fair Value  Unvested at December 31, 2015 264 $ 26.38  Granted 92 30.61  Vested (102) 27.42  Forfeited (39) 26.43  Unvested at December 31, 2016 215 $ 27.69    The total fair value of restricted stock awards vested during the years ended December 31, 2016, 2015, and 2014 were $3.5 million, $3.9 million, and $3.2 million, respectively. The total costs of the options and restricted stock awards charged against income during the years ended December 31, 2016, 2015, and 2014 were $ 3.4 million, $ 3.1 million , and $3.9 million, respectively. Included in share-based compensation expense for 2016 is $0.8 million for 59,375 shares of performance awar ds issuable to certain key employees based on achieving the 2016 financial plan that will vest on December 31, 2017. The Company intends to issue additional performance awards in 2017 to certain key employees that will vest if certain market performance targets are achieved by December 31, 2019. Also included in the 2016 expense, is $0.2 million in expense for 210,000 shares that will vest based on certain market and performance conditions. The total expense of the award based on the Monte Carlo method is $2.0 million which will be recognized evenly through December 2019 . The total income tax benefit recognized in the consolidated statements of income for restricted stock awards was approximately $ 1.2 million, $1.0 million and $ 1.4 million for the years ended December 31, 2016, 2015, and 2014 , respectively . The total tax benefit recognized in additional paid-in capital upon vesting of restricted stock awards and exercise of stock options for the years ended December 31, 2016, 2015, and 2014 was $2 3 0 thousand, $247 thousand and $275 thousand, respectively. There was approximately $3.6 million of total unrecognized compensation cost related to restricted stock awards , excluding $1.8 million of unrecognized compensation expense related to the 210,000 market and performance award shares discussed above, as of December 31, 2016. The cost is expected to be recognized over a weighted-average period of approximately 1.7 years.

Business Segments

Business Segments	12 Months Ended
	Dec. 31, 2016
Business Segments [Abstract]
Business Segments	10. BUSINESS SEGMENTS  Operating segments are components of an enterprise about which separate financial information is available that is regularly reviewed by the chief operating decision maker about how to allocate resources and in assessing performance. The consolidated operating profit of the Company is reviewed by the chief operating decision maker as a single segment and sales are reviewed at the business unit level.  The following table presents sales by business unit for the years ended December 31, 2016, 2015, and 2014:     2016 2015 2014   Take Shape For Life $ 222,402 $ 202,218 $ 206,657  Medifast Direct 35,144 48,658 57,159  MWCC- Franchise 15,669 17,072 15,424  Medifast Wholesale 1,319 4,825 6,045  Revenue $ 274,534 $ 272,773 $ 285,285 

Discontinued Operations, Exit A

Discontinued Operations, Exit Activities, and Clinic Obligations	12 Months Ended
	Dec. 31, 2016
Discontinued Operations, Exit Activities, and Clinic Obligations [Abstract]
Discontinued Operations, Exit Activities, and Clinic Obligations	11. Discontinued Operations, Exit Activities, and Clinic Obligations In 2014, the Company exited the Medifast Weight Control corporate center model by selling 41 company owned centers to existing franchise partners ( 24 centers were sold in June 2014 and the remaining 17 centers were sold in December 2014) and closure of the remaining 34 corporate centers. In accordance with ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity the assets, liabilities, operating results, and cash flows of the corporate Medifast Weight Control Center business unit have been presented separately as discontinued operations in the Consolidated Financial Statements for all periods presented.  The following is a summary of the Company’s operating results for discontinued operations for the years ended December 31, 2016, 2015, and 2014:    2016 2015 2014   Revenue $ - $ - $ 22,509  Income before income taxes from discontinued operations - 878 (13,150)  Income tax provision - 387 (5,302)  Income from discontinued operations, net of tax $ - $ 491 $ (7,848) The following table presents the aggregate carrying amounts of the major classes of assets and liabilities included in discontinued operations as of:    December 31, 2016  ASSETS  Current assets:  Other assets $ 4   Total assets $ 4   LIABILITIES  Current liabilities:  Accounts payable and accrued expenses $ 121   Total liabilities $ 121   Th e following table summarizes the exit obligations, primarily for lease obligations related to closed corporate Medifast Weight Control Centers, severance accruals, and customer refunds incurred as of December 31, 2016:     Accrued balance as of December 31, 2014 $ 6,534  Adjustments recorded during the year (1) (1,483)  Payments during the year (3,922)  Accrued balance as of December 31, 2015 $ 1,129  Adjustments recorded during the year (1) 134  Payments during the year (1,142)  Accrued balance as of December 31, 2016 $ 121   (1)- The adjustments to the accrual recorded relate primarily to agreements reached with franchisees related to lease obligations for previously owned MWCC Corporate Centers.   

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2016
Restructuring [Abstract]
Restructuring	1 2 . Restructuring During the first quarter of 2016, the Company announced the departure of three Executive Vice Presidents in an effort to re-align the senior leadership team to reflect the changing needs of the business and to provide greater emphasis on the Company’s key areas of focus, and also the resignation of the Company’s President and Chief Operating Officer. The Company incurred $1.2 million in net restructuring costs in selling, general, and administrative expense associated with the departure of these four executives. This includes a $0.2 million reversal of costs accrued in 2015 for deferred shares that were granted in connection with the 2015 bonus plan and were forfeited as a result of their departure. The following table summarizes the severance accruals incurred as of December 31, 2016, excluding the reversal of prior year stock accrual:    Accrued balance as of December 31, 2015 $ -  Charges incurred during the year 1,343  Payments during the year (997)  Accrued balance as of December 31, 2016 $ 346 

Impairment

Impairment	12 Months Ended
	Dec. 31, 2016
Impairment [Abstract]
Impairment	13. Impairment During the second quarter of 2016, the Company incurred a $6.1 million impairment charge in connection with the abandonment of software under development for the Take Shape For Life® business unit. The decision to abandon the software, which was determined in the final stages of the quarterly close process, was the result of an in depth analysis of proven alternatives available today in the market which are a better fit for our business going forward and the cost of these alternatives when compared to the ongoing development and maintenance of the abandoned software. The impairment charge was recorded for the full value of the asset and has been included as part of selling, general, and administrative expense on the consolidated statements of income. 

Quarterly Results (unaudited)

Quarterly Results (unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Results (unaudited) [Abstract]
Quarterly Results (unaudited)	14. QUARTERLY RESULTS (unaudited)    First Quarter Second Quarter Third Quarter Fourth Quarter   2016  Revenue $ 72,345 $ 71,144 $ 68,578 $ 62,467  Gross profit 53,194 53,225 52,163 47,082  Income from continuing operations before income taxes 6,359 5,092 9,011 6,660  Income from continuing operations 4,260 3,397 6,065 4,113  Net Income 4,260 3,397 6,065 4,113  Earnings per share from continuing operations- diluted 0.36 0.29 0.51 0.34  Earnings (loss) per share- diluted 0.36 0.29 0.51 0.34   2015  Revenue $ 73,364 $ 72,161 $ 65,936 $ 61,312  Gross profit 53,770 53,167 49,160 45,218  Income from continuing operations before income taxes 6,792 8,828 8,109 5,942  Income from continuing operations 4,416 5,847 5,402 3,902  Net Income 4,444 6,248 5,506 3,860  Earnings per share from continuing operations- diluted 0.36 0.48 0.45 0.33  Earnings (loss) per share- diluted 0.36 0.51 0.46 0.33  Earnings per share (sometimes referred to as “EPS”) is computed independently for each of the quarters presented; accordingly, the sum of the quarterly earnings per share may not equal the total computed for the year. 

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	 15. SUBSEQUENT EVENTS  On March 7, 2017 , the Company’s board of directors declared a $0. 32 cash dividend to its stockholders, valued at $ 3.9 million. The dividend is payable on May 9, 2017 to stockholders of record as of the close of business on March 23, 2017 . 

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Jason Pharmaceuticals, Inc., Take Shape For Life, LLC, Seven Crondall Associates, LLC, Jason Properties, LLC, Medifast Franchise Systems, Inc., Medifast Nutrition, Inc., Optavia LLC, Performance Products LLC, and Jason Enterprises, Inc. All inter-Company transactions and balances have been eliminated in consolidation.
Reclassification	Reclassification – Certain amounts reported for prior periods have been reclassified to be consistent with the current period presentation. No reclassification in the consolidated financial statements had a material impact on the presentation except the reclassification of all deferred tax assets and deferred tax liabilities as noncurrent in accordance with the Company’s early adoption of ASU 2015-17 during the fourth quarter of 2016.
Use of Estimates	Use of Estimates – The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents - Cash and cash equivalents consist of cash on deposit in financial institutions, institutional money funds and other short-term investments with a maturity of 90 days or less at the time of purchase.
Concentration of Credit Risk	Concentration of Credit Risk – Our cash and cash equivalents and available-for-sale securities are maintained at several financial institutions, and the balances with these financial institutions often exceed the amount of insurance provided on such accounts by the Federal Deposit Insurance Corporation. The cash and cash equivalents generally are maintained with financial institutions with reputable credit, and therefore bear minimal credit risk. Historically, we have not experienced any losses due to such concentration of credit risk.
Fair Value of Financial Instruments	Fair Value of Financial Instruments - Our financial instruments include cash and cash equivalents, investment in available-for-sale securities, and trade receivables. The carrying amounts of cash and cash equivalents, and trade receivables approximate fair value due to their short maturities. The fair values of investment in available-for-sale securities are based on dealer quotes.
Accounts Receivable and Allowance for Sales Returns and Doubtful Accounts	Accounts Receivable and Allowance for Sales Returns and Doubtful Accounts - Accounts receivable are recorded net of reserves for sales returns and allowances, and net of provisions for doubtful accounts. We review the reserves for customer returns at each reporting period and adjust them to reflect data available at that time. To estimate reserves for returns, we consider actual return rates in preceding periods. To the extent the estimate of returns changes, we will adjust the reserve, which will impact the amount of product sales revenue recognized in the period of the adjustment. Our estimates for returns have not differed materially from our actual returns. The provision for estimated returns as of December 31, 2016 and 2015 was $394,000 and $323,000 , respectively. Allowances for doubtful accounts are based primarily on an analysis of aged accounts receivable balances and the credit worthiness of our customers as determined by credit checks and analysis, as well as customer payment history. The allowance for doubtful accounts as of December 31, 2016 and 2015 was $55,000 and $94,000 , respectively.
Inventory	Inventory - Inventories consist principally of packaged meal replacements held in the Company’s warehouses. Inventory is stated at the lower of cost or market, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventory for unsalable or obsolete inventory.
Investment Securities	Investment Securities – The Company’s investments consist of debt and equity securities classified as available-for-sale securities. Available-for-sale securities are stated at fair value, and unrealized holding gains and losses, net of the related deferred tax effect, are reported as a separate component of accumulated other comprehensive income in stockholders' equity. Interest and dividends on marketable debt and equity securities are recognized in income when declared. Realized gains and losses, including losses from declines in value of specific securities determined by management to be other-than-temporary, if any, are included in income.
Income Taxes	Income Taxes – The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. We evaluated our tax positions and determined that we did not have any material uncertain tax positions. Our policy is to recognize interest and penalties accrued on uncertain tax positions as part of income tax expense. For the years ending December 31, 2016 and 2015, no material estimated interest or penalties were recognized for the uncertainty of certain tax positions. We file income tax returns in the United States, Canada and various states jurisdictions. We are no longer subject to U.S. federal, state, and local income tax examinations by tax authorities for the years before 2013. Deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Advertising Costs	Advertising Costs - Advertising costs are expensed as incurred, except for the preparation, layout, design and production of advertising costs which are expensed when the advertisement is first used. Advertising expense for continuing operations, excluding broker fees, for the years ended December 31, 2016, 2015, and 2014, amounted to $ 9.4 million, $15.3 million, and $ 17.0 million, respectively.
Operating Leases	Operating Leases - Medifast leases retail stores, distribution facilities, and office space under operating leases. Many of our lease agreements contain tenant improvement allowances, rent holidays, rent escalation clauses, and contingent rent provisions. The Company recognizes incentives and minimum rental expenses on a straight-line basis over the terms of the leases. We commence recording rent expense on the date of initial possession, which is generally when we enter the space and begin to make improvements to properties for our intended use. For tenant improvement allowances and rent holidays, we record a deferred rent liability on the consolidated balance sheets and amortize the deferred rent over the terms of the leases as reductions to rent expense on the consolidated statements of income. For scheduled rent escalation clauses during the lease terms or for rental payments commencing at a date other than the date of initial occupancy, we record minimum rental expenses on a straight-line basis over the terms of the leases on the consolidated statements of income. Several leases provide for contingent rents, which are determined as a percentage of gross sales in excess of specified levels. We record a contingent rent liability on the consolidated balance sheets and the corresponding rent expense when we determine achieving the specified levels is probable.
Clinic Closure Costs	Clinic Closure Costs - Clinic closure costs are expensed and recognized as a liability at their fair value when incurred. One-time employee severance costs are expensed and recognized as a liability when the plan is finalized by management, approved and committed to by management, and communicated to the employee. Contractual costs that will continue to be incurred (operating leases) are recognized at the cease use date. The fair value of operating lease contracts is determined based on the present value of the remaining lease payments. Other costs associated with closing the clinic or relocating employees are expensed as incurred.
Property, Plant, and Equipment	Property, Plant, and Equipment - Property, plant and equipment are stated at cost less accumulated depreciation and amortization. The Company computes depreciation and amortization using the straight-line method over the estimated useful lives of the assets acquired as follows:    Building and building improvements 10 - 35 years  Equipment and fixtures 3 - 15 years  Leasehold Improvements Lease term  Vehicles 5 years  The depreciation life for leasehold improvements is the lesser of the estimated useful life of the addition or the term of the related lease. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.
Research and Development	Research and Development- The Company incurs research and development costs in connection with the development of new products and programs, which are expensed as incurred. The Company also invests in studies to evaluate the effectiveness of our products and programs, the costs of which are recognized evenly over the duration of the study. The Company incurred $2.0 million, $1.8 million, and $1.3 million in research and development expense for the years ended December 31, 2016, 2015, and 2014, respectively.
Revenue Recognition	Revenue Recognition - Revenue is recognized net of discounts, rebates, promotional adjustments, price adjustments, and estimated returns and upon transfer of title and risk to the customer which occurs at shipping (F.O.B. terms). Upon shipment, the Company has no further performance obligations and collection is reasonably assured as the majority of sales are paid prior to shipping. Medifast Weight Control Centers program fees were recognized over the estimated service period.
Shipping and Handling Costs	Shipping and Handling Costs - Our shipping and handling costs for shipments of our product to our customers are included in cost of sales. All shipping and handling charges that are billed to customers are included in net revenue. All other shipping and handling costs are included in selling, general and administration expenses.
Earnings per Share	Earnings per Share - Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of shares of common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of common stock outstanding adjusted for the effect of dilutive common stock equivalents. The following table sets forth the computation of basic and diluted EPS:    Years Ended December 31,  2016 2015 2014  Numerator:  Income from continuing operations $ 17,835 $ 19,567 $ 21,029  Income/(loss) from discontinued operations - 491 (7,848)  Net income $ 17,835 $ 20,058 $ 13,181   Denominator:  Weighted average shares of common stock outstanding 11,842 11,959 12,670  Effect of dilutive common stock equivalents 105 112 108   Weighted average shares of common stock outstanding 11,947 12,071 12,778   EPS:  Basic earnings (loss) per share  Earnings per share from continuing operations $ 1.51 $ 1.64 $ 1.66  Earnings (loss) per share from discontinued operations $ - $ 0.04 $ (0.62)  Earnings per share $ 1.51 $ 1.68 $ 1.04   Diluted earnings per share  Earnings per share from continuing operations $ 1.49 $ 1.62 $ 1.65  Earnings (loss) per share from discontinued operations $ - $ 0.04 $ (0.62)  Earnings per share $ 1.49 $ 1.66 $ 1.03  The calculation of diluted earnings per share excluded 35,000 , 69,375 and 67,375 antidilutive options outstanding for the years ended December 31, 2016, 2015, and 2014 respectively. The calculation of diluted earnings per share for the year ended December 31, 2016 also excluded 93 antidilutive restricted stock awards.
Share-Based Compensation	Share-Based Compensation - Share-based compensation consists primarily of restricted stock awards, market- and performance-based share awards, and stock options granted to employees and directors. Restricted stock awards are measured at the grant date, based on the calculated fair value of the award, and are recognized as an expense over the requisite service period. The fair value of the incentive stock options and non-qualified stock options is calculated using the Black-Scholes option pricing model as of the grant date and recognized over the service period. Market and performance-based share awards that are tied to the Company’s total shareholder return and stock price are valued using the Monte Carlo method and are recognized as expense over the award’s achievement period. The Company issues new shares upon the exercise of stock options and the granting of restricted stock awards.
Comprehensive Income	Comprehensive Income - Other comprehensive income refers to revenues, expenses, gains and losses that are not included in net income but rather are recorded directly in stockholders’ equity. Comprehensive income consists of net income, unrealized gains and losses on available-for-sale securities, and foreign currency translation adjustments.
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have considered all new accounting pronouncements and have concluded that there are no new pronouncements that may have a material impact on our results of operations, financial condition, or cash flows, based on current information, except for: ASU 2016-09, Compensation- Stock Compensation (Topic 718): Improvements to Employee Share-Based Payable Accounting allows for the simplification of accounting for stock compensation in relation to income taxes, classification of awards as equity or liabilities and classification on the statement of cash flows. The pronouncement is effective for fiscal years beginning after December 15, 2016. Management has evaluated the pronouncement and determined that it will not have a material impact on the Company’s financial statements. ASU 2016-02, Leases (Topic 842) requires the rights and obligations of all leased assets with a term greater than 12 months to be presented on the balance sheet. The pronouncement is effective for fiscal years beginning after December 15, 2018. Management is currently evaluating the effect that the provisions of ASU 2016-02 will have on the Company’s financial statements. ASU 2016-01, Financial Instruments- Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities , most notably requires the changes in fair value of equity investments to be recognized in net income. The pronouncement also requires the use of the exit price notion, the separate presentation of financial assets and liabilities by measurement category and form of asset, and the separate presentation in other comprehensive income of changes in fair value resulting from a change in the instrument-specific credit risk. The pronouncement is effective for fiscal years beginning after December 15, 2017. Based on the risk level of the Company’s investment portfolio, Management does not expect the pronouncement to have a material impact on the Company’s financial statements. ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory , requires the Company to recognize inventory at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling price in the ordinary course of business less costs of completion, disposal, and transportation. The pronouncement is effective for fiscal years beginning after December 31, 2016. Management has evaluated the pronouncement and determined that it will not have a material impact on the Company’s financial statements. ASU 2015-09, Revenue from Contracts with Customers (Topic 606) , requires the Company to recognize revenue for the transfer of goods or services to customers for the amount the Company expects to be entitled to in exchange for those goods or services. The Company will be required to identify the contract, identify the relevant performance obligations, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when the entity satisfies a performance obligation. The provisions of this ASU are effective for interim and annual periods beginning after December 15, 2017. Management is evaluating the effect that the provisions of ASU 2015-09 will have on the Company’s financial statements

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies [Abstract]
Property Plant And Equipment Schedule Of Significant Acquisitions And Disposals	Property, plant and equipment are stated at cost less accumulated depreciation and amortization. The Company computes depreciation and amortization using the straight-line method over the estimated useful lives of the assets acquired as follows:    Building and building improvements 10 - 35 years  Equipment and fixtures 3 - 15 years  Leasehold Improvements Lease term  Vehicles 5 years 
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted EPS:    Years Ended December 31,  2016 2015 2014  Numerator:  Income from continuing operations $ 17,835 $ 19,567 $ 21,029  Income/(loss) from discontinued operations - 491 (7,848)  Net income $ 17,835 $ 20,058 $ 13,181   Denominator:  Weighted average shares of common stock outstanding 11,842 11,959 12,670  Effect of dilutive common stock equivalents 105 112 108   Weighted average shares of common stock outstanding 11,947 12,071 12,778   EPS:  Basic earnings (loss) per share  Earnings per share from continuing operations $ 1.51 $ 1.64 $ 1.66  Earnings (loss) per share from discontinued operations $ - $ 0.04 $ (0.62)  Earnings per share $ 1.51 $ 1.68 $ 1.04   Diluted earnings per share  Earnings per share from continuing operations $ 1.49 $ 1.62 $ 1.65  Earnings (loss) per share from discontinued operations $ - $ 0.04 $ (0.62)  Earnings per share $ 1.49 $ 1.66 $ 1.03 

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2016
Financial Instruments [Abstract]
Cash and Available for Sale Securities Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses, and Fair Value by Significant Investment Category	The following table represents cash and the available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or investment securities as of:      December 31, 2016  Cost Unrealized Gains Unrealized Losses Accrued Interest Estimated Fair Value Cash & Cash Equivalents Investment Securities   Cash $ 52,005 $ - $ - $ - $ 52,005 $ 52,005 $ -   Level 1:  Money market accounts 431 - - - 431 431 -  Government & agency securities 2,655 - (48) 9 2,616 - 2,616  3,086 - (48) 9 3,047 431 2,616   Level 2:  Municipal bonds 21,836 - (348) 308 21,796 - 21,796  21,836 - (348) 308 21,796 - 21,796   Total $ 76,927 $ - $ (396) $ 317 $ 76,848 $ 52,436 $ 24,412       December 31, 2015  Cost Unrealized Gains Unrealized Losses Accrued Interest Estimated Fair Value Cash & Cash Equivalents Investment Securities   Cash $ 38,276 $ - $ - $ - $ 38,276 $ 38,276 $ -   Level 1:  Money market accounts 3,761 - - - 3,761 3,761 -  Mutual funds 9,654 37 (444) - 9,247 - 9,247  Corporate equity securities 1,332 246 (76) - 1,502 - 1,502  Government & agency securities 5,425 25 (19) 17 5,448 - 5,448  20,172 308 (539) 17 19,958 3,761 16,197   Level 2:  Municipal bonds 2,735 42 (3) 20 2,794 - 2,794  Corporate bonds 6,054 22 (41) 46 6,081 - 6,081  8,789 64 (44) 66 8,875 - 8,875   Total $ 67,237 $ 372 $ (583) $ 83 $ 67,109 $ 42,037 $ 25,072 

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2016
Inventories [Abstract]
Inventories	Inventories consisted of the following as of:    December 31, 2016 December 31, 2015  Raw materials $ 6,015 $ 3,666  Packaging 1,202 788  Non-food finished goods 701 635  Finished goods 11,219 8,545  Reserve for obsolete inventory (826) (299)  $ 18,311 $ 13,335 

Property, Plant And Equipment (

Property, Plant And Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant, and equipment consisted of the following as of:    December 31, 2016 December 31, 2015  Land $ 565 $ 650  Building and leasehold improvements 12,698 13,122  Equipment and fixtures 42,342 61,573  Vehicles 149 149  $ 55,754 $ 75,494  Less accumulated depreciation and amortization 36,001 46,465  Property, plant and equipment- net $ 19,753 $ 29,029 

Accounts Payable and Accrued 28

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Accounts Payable and Accrued Expenses [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accounts payable and accrued expenses consisted of the following as of:    December 31, 2016 December 31, 2015  Trade payables $ 9,580 $ 11,264  Sales commissions payable 4,757 4,245  Accrued payroll and related taxes 5,402 3,440  Dividends payable 4,039 3,013  Sales tax payable 522 542  $ 24,300 $ 22,504 

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2016
Leases [Abstract]
Future Minimum Rental and Lease Payments	The following table summarizes our future minimum rental and lease payments required under non-cancelable original lease terms in excess of one year as of December 31, 2016:    Operating Leases  2017 $ 1,773  2018 296  2019 21  Total minimum lease payments $ 2,090 
Schedule Of Operating Lease Rent Expense	The following is a summary of the Company’s rent expense for the years ended December 31, 2016, 2015 and 2014:    2016 2015 2014   Continuing operations $ 1,276 $ 1,506 $ 1,460  Discontinued operations - (1,002) 7,189  $ 1,276 $ 504 $ 8,649 

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The components of the income tax expense from continuing operations for the years ended December 31, 2016, 2015, and 2014 are as follows:    2016 2015 2014  Current  Federal $ 11,605 $ 9,814 $ 10,282  State 511 396 96  Total current 12,116 10,210 10,378   Deferred  Federal (3,078) (125) 176  State 253 39 206  Foreign (4) (20) (96)  Total deferred (2,829) (106) 286   Total income tax expense from continuing operations $ 9,287 $ 10,104 $ 10,664 
Schedule Of Components Of Total Income Tax Provision	The total tax provision for the years ended December 31, 2016, 2015, and 2014 was $ 9.0 million, $9.9 million, $4.9 million, respectively. Those amounts have been allocated to the following financial statement items:    2016 2015 2014   Income from continuing operations $ 9,287 $ 10,104 $ 10,664  Income/(loss) from discontinued operations - 387 (5,302)  Stockholders' equity, unrealized gain loss on investment securities & foreign currency (74) (357) (182)  Additional paid in capital, share-based compensation tax benefit (230) (247) (275)   Total income tax expense $ 8,983 $ 9,887 $ 4,905 
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets (liabilities) consisted of the following at December 31,    2016 2015 2014   Reserves on inventory and sales $ 446 $ 199 $ 291  Credit and loss carryforwards 527 735 699  Stock compensation 1,333 1,149 1,283  Accrued expenses and deferred costs 638 1,068 3,170  Inventory capitalization 252 49 142  Sales tax accrual - - 8  Unrealized gain on investments 160 85 -  Total deferred tax assets 3,356 3,285 5,593   Unrealized loss on investments - - (294)  Prepaid expenses (659) (755) (779)  Depreciation (3,453) (6,189) (6,285)  Foreign currency (23) (23) -  Total deferred tax liabilities (4,135) (6,967) (7,358)   Net deferred tax liabilities $ (779) $ (3,682) $ (1,765) 
Schedule of Effective Income Tax Rate Reconciliation	The differences between the United States federal statutory tax rate and the Company's effective tax rate for the years ended December 31, 2016, 2015, and 2014 are as follows:    2016 2015 2014  Statutory federal tax $ 9,493 35.0% $ 10,381 35.0% $ 11,093 35.0%  State income taxes, net of federal benefit 797 2.9% 414 1.4% 314 1.0%  Foreign Taxes 3 0.0% 15 0.1% 73 0.2%  Domestic manufacturer deduction (920) -3.4% (824) -2.8% (811) -2.6%  Other permanent differences 41 0.2% 4 0.0% 200 0.6%  Research and development and jobs credits (163) -0.6% (247) -0.8% (203) -0.6%  Other state income tax benefits - 0.0% 114 0.4% (113) -0.4%  Other 36 0.1% 247 0.8% 111 0.4%  $ 9,287 34.2% $ 10,104 34.1% $ 10,664 33.6% 

Shared-based Compensation (Tabl

Shared-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Share-based Compensation [Abstract]
Schedule of Assumptions Used	The weighted average input assumptions used and resulting fair values were as follows:    2016 2015 2014  Expected term (in years) 6 6 6  Risk-free interest rate 1.11% 1.71% 1.61%  Expected volatility 42.22% 50.91% 63.15%  Dividend yield 3.56% - -   
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes the stock option activity:    Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (Yrs) Aggregate Intrinsic Value  Outstanding at December 31, 2015 98 $ 28.17  Granted 50 27.99  Exercised (12) 25.64  Forfeited (6) 29.87  Expired (1) 31.55  Outstanding at December 31, 2016 129 $ 28.22 8.20 $ 1,736  Exercisable at December 31, 2016 49 $ 27.45 7.31 $ 689   
Restricted Stock Activity	The following table summarizes the restricted stock activity:    Shares Weighted-Average Grant Date Fair Value  Unvested at December 31, 2015 264 $ 26.38  Granted 92 30.61  Vested (102) 27.42  Forfeited (39) 26.43  Unvested at December 31, 2016 215 $ 27.69   

Business Segments (Tables)

Business Segments (Tables)	12 Months Ended
	Dec. 31, 2016
Business Segments [Abstract]
Segment Information	The following table presents sales by business unit for the years ended December 31, 2016, 2015, and 2014:     2016 2015 2014   Take Shape For Life $ 222,402 $ 202,218 $ 206,657  Medifast Direct 35,144 48,658 57,159  MWCC- Franchise 15,669 17,072 15,424  Medifast Wholesale 1,319 4,825 6,045  Revenue $ 274,534 $ 272,773 $ 285,285 

Discontinued Operations, Exit33

Discontinued Operations, Exit Activities, And Clinic Obligations (Tables)	12 Months Ended
	Dec. 31, 2016
Discontinued Operations, Exit Activities, and Clinic Obligations [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures	 The following is a summary of the Company’s operating results for discontinued operations for the years ended December 31, 2016, 2015, and 2014:    2016 2015 2014   Revenue $ - $ - $ 22,509  Income before income taxes from discontinued operations - 878 (13,150)  Income tax provision - 387 (5,302)  Income from discontinued operations, net of tax $ - $ 491 $ (7,848) The following table presents the aggregate carrying amounts of the major classes of assets and liabilities included in discontinued operations as of:    December 31, 2016  ASSETS  Current assets:  Other assets $ 4   Total assets $ 4   LIABILITIES  Current liabilities:  Accounts payable and accrued expenses $ 121   Total liabilities $ 121  
Schedule of Accrued Liabilities	Th e following table summarizes the exit obligations, primarily for lease obligations related to closed corporate Medifast Weight Control Centers, severance accruals, and customer refunds incurred as of December 31, 2016:     Accrued balance as of December 31, 2014 $ 6,534  Adjustments recorded during the year (1) (1,483)  Payments during the year (3,922)  Accrued balance as of December 31, 2015 $ 1,129  Adjustments recorded during the year (1) 134  Payments during the year (1,142)  Accrued balance as of December 31, 2016 $ 121   (1)- The adjustments to the accrual recorded relate primarily to agreements reached with franchisees related to lease obligations for previously owned MWCC Corporate Centers.   

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
	Dec. 31, 2016
Restructuring [Abstract]
Restructuring and Related Costs	The following table summarizes the severance accruals incurred as of December 31, 2016, excluding the reversal of prior year stock accrual:    Accrued balance as of December 31, 2015 $ -  Charges incurred during the year 1,343  Payments during the year (997)  Accrued balance as of December 31, 2016 $ 346 

Quarterly Results (unaudited) (

Quarterly Results (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Results (unaudited) [Abstract]
Quarterly Financial Information	  First Quarter Second Quarter Third Quarter Fourth Quarter   2016  Revenue $ 72,345 $ 71,144 $ 68,578 $ 62,467  Gross profit 53,194 53,225 52,163 47,082  Income from continuing operations before income taxes 6,359 5,092 9,011 6,660  Income from continuing operations 4,260 3,397 6,065 4,113  Net Income 4,260 3,397 6,065 4,113  Earnings per share from continuing operations- diluted 0.36 0.29 0.51 0.34  Earnings (loss) per share- diluted 0.36 0.29 0.51 0.34   2015  Revenue $ 73,364 $ 72,161 $ 65,936 $ 61,312  Gross profit 53,770 53,167 49,160 45,218  Income from continuing operations before income taxes 6,792 8,828 8,109 5,942  Income from continuing operations 4,416 5,847 5,402 3,902  Net Income 4,444 6,248 5,506 3,860  Earnings per share from continuing operations- diluted 0.36 0.48 0.45 0.33  Earnings (loss) per share- diluted 0.36 0.51 0.46 0.33 

Summary of Significant Accoun36

Summary of Significant Accounting Policies (Narrative) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Provision for estimated returns	$ 394,000	$ 323,000
Allowance for doubtful accounts	55,000	94,000
Advertising expense	9,400,000	15,300,000	$ 17,000,000
Research and development expense	$ 2,000,000	$ 1,800,000	$ 1,300,000
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive awards	35,000	69,375	67,375
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive awards	93

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Summary of Estimated Useful Lives Of Assets) (Detail)	12 Months Ended
	Dec. 31, 2016
Building and Building Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	10 years
Building and Building Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	35 years
Equipment and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Equipment and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	15 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment leasehold improvements useful life	Lease term
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Earnings per Share) (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Numerator:
Income from continuing operations	$ 4,113	$ 6,065	$ 3,397	$ 4,260	$ 3,902	$ 5,402	$ 5,847	$ 4,416	$ 17,835	$ 19,567	$ 21,029
Income from discontinued operations										491	(7,848)
Net income	$ 4,113	$ 6,065	$ 3,397	$ 4,260	$ 3,860	$ 5,506	$ 6,248	$ 4,444	$ 17,835	$ 20,058	$ 13,181
Denominator:
Weighted average shares of common stock outstanding									11,842	11,959	12,670
Effect of dilutive common stock equivalents									105	112	108
Weighted average shares of common stock outstanding									11,947	12,071	12,778
Basic earnings (loss) per share
Earnings per share from continuing operations									$ 1.51	$ 1.64	$ 1.66
Earnings per share from discontinued operations										0.04	(0.62)
Earnings per share									1.51	1.68	1.04
Diluted earnings (loss) per share
Earnings per share from continuing operations	$ 0.34	$ 0.51	$ 0.29	$ 0.36	$ 0.33	$ 0.45	$ 0.48	$ 0.36	1.49	1.62	1.65
Earnings per share from discontinued operations										0.04	(0.62)
Earnings per share	$ 0.34	$ 0.51	$ 0.29	$ 0.36	$ 0.33	$ 0.46	$ 0.51	$ 0.36	$ 1.49	$ 1.66	$ 1.03

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Financial Instruments [Line Items]
Realized Gain (Loss) on Marketable Securities, Cost Method Investments, and Other Investments	$ (313)	$ 458	$ 771
US Treasury and Government Short-term Debt Securities [Member]
Financial Instruments [Line Items]
Available for Sale Securities Maturity Period	5 years

Financial Instruments (Cash and

Financial Instruments (Cash and Available for Sale Securities Adjusted Cost, Gross Unrealized Gains, Gross Unrealized Losses, and Fair Value by Significant Investment Category) (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	$ 76,927	$ 67,237
Unrealized Gains		372
Unrealized Losses	(396)	(583)
Accrued Interest	317	83
Estimated Fair Value	76,848	67,109
Cash & Cash Equivalents	52,436	42,037	$ 24,459	$ 36,382
Investment Securities	24,412	25,072
Cash [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	52,005	38,276
Estimated Fair Value	52,005	38,276
Cash & Cash Equivalents	52,005	38,276
Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	3,086	20,172
Unrealized Gains		308
Unrealized Losses	(48)	(539)
Accrued Interest	9	17
Estimated Fair Value	3,047	19,958
Cash & Cash Equivalents	431	3,761
Investment Securities	2,616	16,197
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	431	3,761
Estimated Fair Value	431	3,761
Cash & Cash Equivalents	431	3,761
Fair Value, Inputs, Level 1 [Member] | Mutual Funds [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost		9,654
Unrealized Gains		37
Unrealized Losses		(444)
Estimated Fair Value		9,247
Investment Securities		9,247
Fair Value, Inputs, Level 1 [Member] | Corporate Equity Securities [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost		1,332
Unrealized Gains		246
Unrealized Losses		(76)
Estimated Fair Value		1,502
Investment Securities		1,502
Fair Value, Inputs, Level 1 [Member] | Government and Agency Securities [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	2,655	5,425
Unrealized Gains		25
Unrealized Losses	(48)	(19)
Accrued Interest	9	17
Estimated Fair Value	2,616	5,448
Investment Securities	2,616	5,448
Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	21,836	8,789
Unrealized Gains		64
Unrealized Losses	(348)	(44)
Accrued Interest	308	66
Estimated Fair Value	21,796	8,875
Investment Securities	21,796	8,875
Fair Value, Inputs, Level 2 [Member] | Municipal Bonds [Member]
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	21,836	2,735
Unrealized Gains		42
Unrealized Losses	(348)	(3)
Accrued Interest	308	20
Estimated Fair Value	21,796	2,794
Investment Securities	$ 21,796	2,794
Fair Value, Inputs, Level 2 [Member] | Corporate Bonds
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost		6,054
Unrealized Gains		22
Unrealized Losses		(41)
Accrued Interest		46
Estimated Fair Value		6,081
Investment Securities		$ 6,081

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventories [Abstract]
Raw Materials	$ 6,015	$ 3,666
Packaging	1,202	788
Non-food Finished Goods	701	635
Finished Goods	11,219	8,545
Reserve for Obsolete Inventory	(826)	(299)
Inventory	$ 18,311	$ 13,335

Property, Plant and Equipment42

Property, Plant and Equipment (Narrative) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Weight Control Centers [Member]
Asset impairment loss			$ (3.3)
Continuing Operations [Member]
Depreciation and amortization	$ 5.4	$ 7.1	8.1
Discontinued Operations [Member] | Weight Control Centers [Member]
Depreciation and amortization	$ 0	$ 0	$ 1.7

Property, Plant And Equipment43

Property, Plant And Equipment (Property, Plant and Equipment) (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 55,754	$ 75,494
Less accumulated depreciation and amortization	36,001	46,465
Property, plant and equipment- net	19,753	29,029
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	565	650
Building and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	12,698	13,122
Equipment and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	42,342	61,573
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 149	$ 149

Accounts Payable and Accrued 44

Accounts Payable and Accrued Expenses (Accounts Payable and Accrued Expenses) (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accounts Payable and Accrued Liabilities [Abstract]
Trade payables	$ 9,580	$ 11,264
Sales commissions payable	4,757	4,245
Accrued payroll and related taxes	5,402	3,440
Dividends payable	4,039	3,013
Sales tax payable	522	542
Total	$ 24,300	$ 22,504

Leases (Narrative) (Detail)

Leases (Narrative) (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)agreement	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)agreement
Operating and Capital Leases [Line Items]
Sublease rent	$ 800,000
Equipment lease expense	$ 700,000	$ 1,000,000	$ 1,200,000
Operating leases | agreement	20
Number of leased centers closed | agreement	3
Number of sublease agreements | agreement			17
Discontinued Operations [Member]
Operating and Capital Leases [Line Items]
Rent expense accrual			$ 4,400,000
Minimum [Member]
Operating and Capital Leases [Line Items]
Control Centers leases monthly price range	$ 1,800
Control Centers leases term	5 years
Maximum [Member]
Operating and Capital Leases [Line Items]
Control Centers leases monthly price range	$ 4,200
Control Centers leases term	10 years

Leases (Future Minimum Rental a

Leases (Future Minimum Rental and Lease Payments) (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Leases [Abstract]
Operating Leases 2017	$ 1,773
Operating Leases 2018	296
Operating Leases 2019	21
Operating leases, Total minimum lease payments	$ 2,090

Leases (Summary of Company's Re

Leases (Summary of Company's Rent Expense) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Rent expense	$ 1,276	$ 504	$ 8,649
Continuing Operations [Member]
Rent expense	$ 1,276	1,506	1,460
Discontinued Operations [Member]
Rent expense		$ (1,002)	$ 7,189

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Tax Credit Carryforward [Line Items]
Operating Loss Carryforwards Expiration Year	2,031
Operating Loss Carryforwards	$ 8,000
Income Tax Expense (Benefit), Intraperiod Tax Allocation, Total	8,983	$ 9,887	$ 4,905
Tax Credit Carryforward, Amount	$ 110
Tax Credit Carryforward Expiration Year	2,022
Deferred Tax Liabilities, Net, Noncurrent	$ 779	3,682
Accounting Standards Update 2015-17 [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets Reclassified, Current	$ 1,700	$ 1,200	$ 3,700
Maryland State [Member]
Tax Credit Carryforward [Line Items]
Operating Loss Carryforwards Expiration Year	2,017
Operating Loss Carryforwards	$ 116

Income Taxes (Income Tax Expens

Income Taxes (Income Tax Expense from Continuing Operations) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current
Federal	$ 11,605	$ 9,814	$ 10,282
State	511	396	96
Total Current	12,116	10,210	10,378
Deferred
Federal	(3,078)	(125)	176
State	253	39	206
Foreign	(4)	(20)	(96)
Total Deferred	(2,829)	(106)	286
Income Tax Expense, Total	$ 9,287	$ 10,104	$ 10,664

Income Taxes (Summary of Tax Pr

Income Taxes (Summary of Tax Provision Allocation to Financial Statement Items) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Income from continuing operations	$ 9,287	$ 10,104	$ 10,664
Income/(loss) from discontinued operations		387	(5,302)
Stockholders' equity, unrealized gain (loss) on investment securities & foreign currency	(74)	(357)	(182)
Additional paid in capital, share-based compensation tax benefit	(230)	(247)	(275)
Total Income Tax Expense	$ 8,983	$ 9,887	$ 4,905

Income Taxes (Deferred Tax Asse

Income Taxes (Deferred Tax Assets (Liabilities)) (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Reserves on inventory and sales	$ 446	$ 199	$ 291
Credit and loss carryforwards	527	735	699
Stock compensation	1,333	1,149	1,283
Accrued expenses and deferred costs	638	1,068	3,170
Inventory capitalization	252	49	142
Sales tax accrual			8
Unrealized gain/loss on investments	160	85
Total deferred tax assets	3,356	3,285	5,593
Unrealized loss on investments			(294)
Prepaid expenses	(659)	(755)	(779)
Depreciation	(3,453)	(6,189)	(6,285)
Foreign currency	(23)	(23)
Total deferred tax liabilities	(4,135)	(6,967)	(7,358)
Net deferred tax liabilities	$ (779)	$ (3,682)	$ (1,765)

Income Taxes (Statutory Tax Rat

Income Taxes (Statutory Tax Rate and Effective Tax Rate) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Statutory federal tax	$ 9,493	$ 10,381	$ 11,093
State income taxes, net of federal benefit	797	414	314
Foreign Taxes	3	15	73
Domestic manufacturer deduction	(920)	(824)	(811)
Other permanent differences	41	4	200
Research and development and jobs credits	(163)	(247)	(203)
Other state income tax benefits		114	(113)
Other	36	247	111
Income Tax Expense (Benefit), Total	$ 9,287	$ 10,104	$ 10,664
Effective tax rate, Statutory federal tax	35.00%	35.00%	35.00%
Effective tax rate, State income taxes, net of federal benefit	2.90%	1.40%	1.00%
Effective Income Tax Rate Reconciliation, Foreign Taxes	0.00%	0.10%	0.20%
Effective tax rate, Domestic manufacturer deduction	(3.40%)	(2.80%)	(2.60%)
Effective tax rate, Other permanent differences	0.20%	0.00%	0.60%
Effective tax rate, Research and development and jobs credits	(0.60%)	(0.80%)	(0.60%)
Effective tax rate, Other state income tax benefits	0.00%	0.40%	(0.40%)
Effective tax rate, Other	0.10%	0.80%	0.40%
Effective tax rate, Total	34.20%	34.10%	33.60%

Shared-based Compensation (Narr

Shared-based Compensation (Narrative) (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 3,428	$ 3,081	$ 3,918
Total income tax benefit recognized related to restricted stock awards	230	247	275
Proceeds from stock options exercised	299	44	0
Share-based compensation tax benefit	230	247	275
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	3,400	3,100	3,900
Total income tax benefit recognized related to restricted stock awards	1,200	1,000	1,400
Employee service share based compensation nonvested awards total compensation cost not yet recognized	$ 3,600
Compensation cost recognition weighted average period	1 year 8 months 12 days
Award vesting period	5 years
Shares granted	92,000
Share-based compensation arrangement, fair value of awards vested	$ 3,500	3,900	$ 3,200
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share based compensation nonvested awards total compensation cost not yet recognized	$ 500
Compensation cost recognition weighted average period	1 year 8 months 12 days
Award vesting period	3 years
Share-based compensation, shares authorized under stock option plans, exercise price range, lower range limit	$ 24.26
Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value	7.91
Share-based compensation, shares authorized under stock option plans, exercise price range, upper range limit	$ 31.55
Share based compensation arrangement by share based payment award options expiration term	10 years
Intrinsic value of options exercised	$ 69	$ 10
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share based compensation nonvested awards total compensation cost not yet recognized	1,800
Time-Based Restircted Shares [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 800
Share-based compensation arrangement shares to be issued	59,375
Deferred Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 200
Share-based compensation arrangement shares to be issued	210,000
Cost of the award	$ 2,000
Award recognition period end date	Dec. 31, 2019

Shared-based Compensation (Sche

Shared-based Compensation (Schedule of Assumptions Used) (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation [Abstract]
Expected term (in years)	6 years	6 years	6 years
Risk-free interest rate	1.11%	1.71%	1.61%
Expected volatility	42.22%	50.91%	63.15%
Dividend yield	3.56%

Shared-based Compensation (Sc55

Shared-based Compensation (Schedule of Share Based Compensation Stock Options Activity) (Detail) - Stock Option [Member] $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, Outstanding Beginning Balance | shares	98
Shares, Granted | shares	50
Shares, Exercised | shares	(12)
Shares, Forfeited | shares	(6)
Shares, Expired | shares	(1)
Shares, Outstanding Ending Balance | shares	129
Shares, Exerciseable | shares	49
Weighted-Average Exercise Price, Outstanding Beginning Balance | $ / shares	$ 28.17
Weighted-Average Exercise Price, Granted | $ / shares	27.99
Weighted-Average Exercise Price, Exercised | $ / shares	25.64
Weighted-Average Exercise Price, Forfeited | $ / shares	29.87
Weighted-Average Exercise Price, Expired | $ / shares	31.55
Weighted-Average Exercise Price, Oustanding Ending Balance | $ / shares	28.22
Weighted-Average Exercise Price, Exerciseable | $ / shares	$ 27.45
Weighted-Average Remaining Contractual Life (Yrs), Outstanding	8 years 2 months 12 days
Weighted-Average Remaining Contractual Life (Yrs), Exerciseable	7 years 3 months 22 days
Aggregate Intrinsic Value, Outstanding | $	$ 1,736
Aggregate Intrinsic Value, Exerciseable | $	$ 689

Shared-based Compensation (Summ

Shared-based Compensation (Summary of Restricted Stock Activity) (Detail) - Restricted Stock [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Shares
Unvested at December 31, 2015 | shares	264
Granted | shares	92
Vested | shares	(102)
Forfeited | shares	(39)
Unvested at December 31, 2016 | shares	215
Weighted-Average Grant Date Fair Value
Unvested at December 31, 2015 | $ / shares	$ 26.38
Granted | $ / shares	30.61
Vested | $ / shares	27.42
Forfeited | $ / shares	26.43
Unvested at December 31, 2016 | $ / shares	$ 27.69

Business Segments (Sales by Cha

Business Segments (Sales by Channel) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Net Revenue	$ 274,534	$ 272,773	$ 285,285
Take Shape For Life [Member]
Segment Reporting Information [Line Items]
Net Revenue	222,402	202,218	206,657
Medifast Direct [Member]
Segment Reporting Information [Line Items]
Net Revenue	35,144	48,658	57,159
Franchise Weight Control Centers [Member]
Segment Reporting Information [Line Items]
Net Revenue	15,669	17,072	15,424
Medifast Wholesale [Member]
Segment Reporting Information [Line Items]
Net Revenue	$ 1,319	$ 4,825	$ 6,045

Discontinued Operations, Exit58

Discontinued Operations, Exit Activities, and Clinic Obligations (Narrative) (Detail) - store	1 Months Ended		12 Months Ended
	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2014
Discontinued Operations, Exit Activities, and Clinic Obligations [Abstract]
Corporate Centers Sold During Period	17	24	41
Corporate Centers Closed During Period			34

Discontinued Operations, Exit59

Discontinued Operations, Exit Activities, and Clinic Obligations (Summary of Company's Operating Results for Discontinued Operations) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Discontinued Operations, Exit Activities, and Clinic Obligations [Abstract]
Revenue		$ 22,509
Income before income taxes from discontinued operations	$ 878	(13,150)
Income tax provision	387	(5,302)
Income from discontinued operations, net of tax	$ 491	$ (7,848)

Discontinued Operations, Exit60

Discontinued Operations, Exit Activities, and Clinic Obligations (Major Classes of Assets and Liabilities) (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Current assets:
Other assets	$ 4
Total assets	4
Current liabilities:
Accounts payable and accrued expenses	121
Total liabilities	$ 121

Discontinued Operations, Exit61

Discontinued Operations, Exit Activities, and Clinic Obligations (Summary of Accrued) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Discontinued Operations, Exit Activities, and Clinic Obligations [Abstract]
Accrued Balance	$ 1,129	$ 6,534
Adjustments recorded during the period	134	(1,483)
Payments during the period	(1,142)	(3,922)
Accrued Balance	$ 121	$ 1,129

Restructuring (Narrative) (Deta

Restructuring (Narrative) (Detail) - Bonus Plan 2015 [Member] $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Accrued costs reversal	$ 0.2
Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost	$ 1.2

Restructuring (Severance Accrua

Restructuring (Severance Accruals Incurred) (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Restructuring [Abstract]
Ending accrued balance as of December 31, 2015
Charges incurred during the period	1,343
Payments during the period	(997)
Ending accrued balance as of December 31, 2016	$ 346

Impairment (Narrative) (Detail)

Impairment (Narrative) (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2016
Impairment [Abstract]
Impairment of Long-Lived Assets Held-for-use	$ 6,100	$ 6,083

Quarterly Results (unaudited)65

Quarterly Results (unaudited) (Quarterly Financial Information) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Quarterly Results (unaudited) [Abstract]
Revenue	$ 62,467	$ 68,578	$ 71,144	$ 72,345	$ 61,312	$ 65,936	$ 72,161	$ 73,364	$ 274,534	$ 272,773	$ 285,285
Gross profit	47,082	52,163	53,225	53,194	45,218	49,160	53,167	53,770	205,664	201,315	209,207
Income from continuing operations before income taxes	6,660	9,011	5,092	6,359	5,942	8,109	8,828	6,792	27,122	29,671	31,693
Income from continuing operations	4,113	6,065	3,397	4,260	3,902	5,402	5,847	4,416	17,835	19,567	21,029
Net income	$ 4,113	$ 6,065	$ 3,397	$ 4,260	$ 3,860	$ 5,506	$ 6,248	$ 4,444	$ 17,835	$ 20,058	$ 13,181
Earnings per share from continuing operations- diluted	$ 0.34	$ 0.51	$ 0.29	$ 0.36	$ 0.33	$ 0.45	$ 0.48	$ 0.36	$ 1.49	$ 1.62	$ 1.65
Earnings (loss) per share- diluted	$ 0.34	$ 0.51	$ 0.29	$ 0.36	$ 0.33	$ 0.46	$ 0.51	$ 0.36	$ 1.49	$ 1.66	$ 1.03

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) $ / shares in Units, $ in Millions	Mar. 07, 2017USD ($)$ / shares
Subsequent Event [Line Items]
Dividends Payable, Amount Per Share | $ / shares	$ 0.32
Subsequent Event [Member]
Subsequent Event [Line Items]
Dividends Payable | $	$ 3.9
Dividends Payable, Date to be Paid	May 9, 2017
Dividends Payable, Date of Record	Mar. 23, 2017
Dividends Payable, Date Declared	Mar. 7, 2017